Personal information
Surname(s) / First name(s) / Peraldo Neia Caterina
Address
Telephone
Fax
E-mail /
Nationality / Italian
Date of birth / 26/02/1983
Gender / Female
Work experience
dates• / January 2009 - Today
Name and address of employer / Institute for Cancer Research and Treatment (IRCC), Strada provinciale 142, km 3,95, 10060, Candiolo, Torino
Fondazione Edo ed Elvo Tempia Valenta, Via Malta 3, 13900, Biella
Type of business or sector / Cancer Research, Cancer Genomic Lab
Occupation or position held / Ph.D student in Human Oncology at University of Turin, Italy
• Main activities and responsibilities / Identification of new molecular targets in cholangiocarcinoma; testing efficacy of new drugs alone or in combination with chemotherapy in this pathology
dates• / January 2008 – December 2008
Name and address of employer / Institute for Cancer Research and Treatment (IRCC), Strada provinciale 142, km 3,95, 10060, Candiolo, Torino
Fondazione Edo ed Elvo Tempia Valenta, Via Malta 3, 13900, Biella
Type of business or sector / Cancer Research, Cancer Genomic Lab
Occupation or position held / Scholarship holder at Fondazione Edo ed Elvo Tempia Valenta
• Main activities and responsibilities / Gene expression profiling, mutational analysis, protein expression of Epidermal Growth Factor Receptor (EGFR) in prostate cancer patients.
dates• / October 2005 – October 2007
Name and address of employer / Institute for Cancer Research and Treatment (IRCC), Strada provinciale 142, km 3,95, 10060, Candiolo, Torino
Fondazione Edo ed Elvo Tempia Valenta, Via Malta 3, 13900, Biella
Type of business or sector / Cancer Research, Cancer Genomic Lab
Occupation or position held / Trainee at IRCC-Candiolo and Fondazione Edo ed Elvo Tempia Valenta
• Main activities and responsibilities / DNA and RNA extraction, PCR, mutational analysis, sequences analysis using Chromas, IHC, gene expression profiling of prostate cander patients by microarray.
date / •May 2005 – September 2005
• Nome e indirizzo del datore di lavoro / Institute for Cancer Research and Treatment (IRCC), Strada provinciale 142, km 3,95, 10060, Candiolo, Torino
• Tipo di azienda o settore / Cancer Research
• Tipo di impiego / Trainee
• Principali mansioni e responsabilità / DNA extraction, PCR, mutational analysis, sequences analysis using Chromas.
Education and training
Dates / September 2005 – October 2007
Name and type of organisation providing education and training / University of Turin, Italy
Principal subjects/occupational skills covered / Molecular Biology, Cellular Biology, Biochemestry, Microbiology
Title of qualification awarded / Master degree in Biomolecular Science, with 108/110. Title of thesis: “Expression and mutations of EGFR and gene expression profilng in prostate cancer”.
Level in national or international classification / Master degree
Dates / September 2002 – September 2005
Name and type of organisation providing education and training / University of Turin, Italy
Principal subjects/occupational skills covered / Elements of Molecular Biology, Cellular Biology, Biochemestry
Title of qualification awarded / Bachelor degree in Biological Science with 96/110. Title of thesis: “Mutational analysis of epidermal growth factor in cholangiocarcinoma”
Level in national or international classification / Bachelor degree
Dates / September 1997- June 2002
Name and type of organisation providing education and training / Classic Lyceum “Massimo D’Azeglio”, Via Parini, 8 10121, Torino, Italy
Principal subjects/occupational skills covered / Italian, Latin, Classical Greek, History, Philosophy, Science, English, Art, Physics, Maths
Title of qualification awarded / Graduate at Classic Lyceum with 84/100.
Level in national or international classification / Graduation
Personal skills and competences .
Other language
English
• Understanding / Excellent
• Speaking / Very Good
• Writing / Very good
Social skills and competences. / Ability to work in team.
Good autonomy
Organisational skills and competences. / Experience in voluntary association, parish summer camps
Technical skills and competences. / · DNA and RNA extraction from fresh tissues, paraffin-embadded tissues, cell lines, blood
· Sequences analysis using “Chromas” software
· Immunohistochemistry on paraffin-embadded or Glyofixx embedded tissues
· Immunocytochemistry and Immunofluorescence
· Cultures of cancer cell lines
· In vitro assay to test antiproliferative effect of drugs, migration and invasion
· Western Blot analysis
· Amplification and purification of nucleic acids.
· Qualitative and quantitative control of RNA by BioAnalyzer (Agilent)
· Labelling and Hybridization of probes for gene expression profiling by microarray
· Validation of microarray data by Real-Time RT-PCR
· Animal manipulation
· Ability to use principle browsers to obtain data of biological importance
· Good skill of Windows and its applications ( word, excel, power point)
Driving licence / Driver licence B
Additional information / December 2007: State exam for biologist profession
Publications:
· Peraldo-Neia C, Migliardi G, Mello-Grand M, Montemurro F, Segir R, Pignochino Y, Cavalloni G, Torchio B, Mosso L, Chiorino G, Aglietta M. Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer. BMC Cancer. 2011 Jan 25;11:31. PubMed PMID: 21266046.
· Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. Breast Cancer Res Treat. 2010 Dec 9.[Epub ahead of print] PubMed PMID: 21153051.
· Pignochino Y, Sarotto I, Peraldo-Neia C, Penachioni JY, Cavalloni G, Migliardi G, Casorzo L, Chiorino G, Risio M, Bardelli A, Aglietta M, Leone F. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer. 2010 Nov 18;10:631. PubMed PMID: 21087480
· Cavalloni G, Peraldo Neia C, Sarotto I, Gammaitoni L, Migliardi G, Soster M
Marchio S, Aglietta M, Leone F. Antitumor activity of Src inhibitor Saracatinib
(AZD-0530) in preclinical models of biliary tract carcinomas. Mol Cancer Ther.
2012 Mar 27. [Epub ahead of print] PubMed PMID: 22452946.
Poster
l Caterina Peraldo Neia1,2, Giorgia Migliardi1, Maurizia Mello Grand2, Raffaella Segir2, Ymera Pignochino1, Giuliana Cavalloni1, Bruno Torchio3, Luciano Mosso3, Giovanna Chiorino2, Massimo Aglietta1 “Gene profiling, expression and mutations of Epidermal Growth Factor Receptor (EGFR) in androgen-dependent prostate cancer”. Abstract accepted at 21st Pezcoller Symposium
l Peraldo Neia Caterina, Pignochino Ymera, Cavalloni Giuliana , Sarotto Ivana, Aglietta Massimo, Leone Francesco “Enhancement of antiproliferative effect of gemcitabine by EGFR and HER2 pathway inhibition in bile duct carcinomas”. Abstract accpeted at 51° Congresso Nazionale della Società Italiana di Cancerologia
l Giorgio Valabrega1,2, Sonia Capellero2, Giuliana Cavalloni2, Gianluca Zaccarello3 , Annalisa Petrelli4, Giorgia Migliardi2, Andrea Milani1, Caterina Peraldo Neia5, Loretta Gammaitoni2, Francesco Favero5, Aldo Moggio2, Silvia Giordano1,4, Massimo Aglietta1,2 and Filippo Montemurro2 “HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and become sensitive to the multitargeted kinase inhibitor sorafenib”. Abstract accepted at 2009 Molecular Targets and Cancer Therapeutics
l Dario Sangiolo, MD, PhD1, Giorgio Valabrega, MD2*, Giuliana Cavalloni, PhD2*, Sonia Capellero3*, Giulia Mesiano4*, Maja Todorovic1*, Cristina Cammarata5*, Caterina Peraldo Neia2*, Wanda Piacibello, MD6, Alessandro Cignetti, MD, PhD1* and Massimo Aglietta, MD4* “MIC A/B Protein Expression Associates with Trastuzumab-Resistant Breast Cancer Cells Leading to Effective Immunotherapy by Cytokine Induced Killer Cells”. Abstract accepted at ASH 2009.
· Sonia Capellero, Giuliana Cavalloni, Andrea Milani, Caterina Peraldo-Neia, Anna Sapino, Carla Pecchioni4, Massimo Aglietta, Filippo Montemurro. Overcoming Trastuzumab resistance in HER2-overexpressing breast cancer cells by multikinase inhibitor Sorafenib. Accepted at 52nd Annual Meeting of the Italian Cancer Society Rome.
· Caterina Peraldo Neia1, Giovanni Grignani2, Giorgia Migliardi1, Giuliana Cavalloni1, Alberto Pisacane3, Sandra Aliberti2, Ymera Pignochino, 1 Mauro Risio3, Massimo Aglietta2 Role of CXCR4/SDF-1 axis in soft tissue sarcoma progression Accepted at 52nd Annual Meeting of the Italian Cancer Society Rome.
Additional information / · Leone Francesco, Peraldo-Neia Caterina, Cavalloni Giuliana, Colombi Federica, Aglietta Massimo. AZD0530 (saracatinib) inhibits biliary cancer cell motility and invasion. Accepted at ASCO GI 2011
· Peraldo-Neia Caterina, Cavalloni Giuliana, Leone Francesco, Giorgia Migliardi, Loretta Gammaitoni, Aglietta Massimo. “Anti-tumor activity of Src inhibitor AZD-0530 in biliary carcinoma preclinical models”- accepted at 2011 International Conference “Molecular Clinical Oncology”, Turin.
Pagina 4 - Curriculum vitae di
[ PERALDO NEIA Caterina ]